+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gemcitabine Hydrochloride Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997541
  • Report
  • March 2020
  • Region: Global
  • 117 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Accord Healthcare Inc.
  • Apotex Inc.
  • Eli Lilly & Co.
  • Fressenius Kabi USA
  • Gland Pharma Ltd.
  • Teva Pharmaceuticals Ltd.
  • MORE
The Gemcitabine Hydrochloride Market is expected to register a CAGR of 7.1% during the forecast period. Growing research & development activities and growing burden of cancer diseases is expected to drive the gemcitabine hydrochloride market growth. According to World Health Organization, the incidence of cancer in 2018 was around 18.1 million worldwide. Furthermore, approximately 9.6 million of deaths occurred globally and Europe accounts for 20.3% of deaths. According to a study published in MDPI, in 2019, co-delivering technique in case of gemcitabine hydrochloride enhanced the survival rate in pancreatic patients. However, the rigorous regulatory framework for approvals of the product may impel the global gemcitabine hydrochloride market growth.

Key Market Trends

Lung Cancer Segment is Expected to Hold a Major Market Share in the Gemcitabine Hydrochloride Market
  • Lung Cancer has registered highest number of deaths, i.e., 1.8 million (approximately) worldwide according to the World Health Organization. Furthermore, lung cancer is among the top five cancers in terms of incidence rate. According to the World Health Organization, around 2.1 million new cases of lung cancer were diagnosed worldwide. Lung cancer commonly occurs in men, around 22% of deaths of lung cancer caused in men. According to the same source, around 14.5% is affected to men out of total cases of lung cancer. Non-small cell lung cancer is the most prevalent one. According to American Cancer Society, around 84% of lung cancer is non-small cell lung cancer.
  • Also, research & development activities related to lung cancer is expected to boost this segment. According to the study published by MDPI in 2019, gemciatbine hydrochloride in combination with Danggui Buxue decoction exhibited the enhanced inhibition effect for tumor growth in lungs.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global gemcitabine hydrochloride market due to increasing burden of cancer diseases and advancement in product. Breast cancer is usually caused due to abnormal growth of cells in the tissues that are made up of glands (invasive) or in the ducts (in-situ). According to the American Cancer Society, Inc. in 2017, around 63,410 new cases were diagnosed in women in the United States. Moreover, approximately, 252,710 new cases were diagnosed with invasive breast cancer.

Competitive Landscape

The Gemcitabine Hydrochloride Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Eli Lilly & Co., Accord Healthcare Inc., Pfizer Inc. (Hospira Inc.), Apotex Inc., Fressenius Kabi USA, Gland Pharma Ltd., Mylan Pharmaceuticals Inc., Sagent Pharmaceuticals Inc., Teva Pharmaceuticals Ltd. and JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Accord Healthcare Inc.
  • Apotex Inc.
  • Eli Lilly & Co.
  • Fressenius Kabi USA
  • Gland Pharma Ltd.
  • Teva Pharmaceuticals Ltd.
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer
4.2.2 Increasing Research & Development Activities
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Injection
5.1.2 Solution
5.2 By Indication
5.2.1 Breast Cancer
5.2.2 Non-small Cell Lung Cancer
5.2.3 Pancreatic Cancer
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Accord Healthcare Inc.
6.1.2 Apotex Inc.
6.1.3 Eli Lilly & Co.
6.1.4 Fressenius Kabi USA
6.1.5 Gland Pharma Ltd.
6.1.6 JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
6.1.7 Mylan Pharmaceuticals Inc.
6.1.8 Pfizer Inc. (Hospira Inc.)
6.1.9 Sagent Pharmaceuticals Inc.
6.1.10 Teva Pharmaceuticals Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Accord Healthcare Inc.
  • Apotex Inc.
  • Eli Lilly & Co.
  • Fressenius Kabi USA
  • Gland Pharma Ltd.
  • JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
  • Mylan Pharmaceuticals Inc.
  • Pfizer Inc. (Hospira Inc.)
  • Sagent Pharmaceuticals Inc.
  • Teva Pharmaceuticals Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll